- Datum25.09.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Compass Pathways PLC (Spons.ADRs) o.N.
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Compass Pathways PLC (Spons.ADRs) o.N. Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,11 %
Intraday
6,57 %
1 Woche
4,58 %
1 Monat
-16,57 %
Seit Jahresbeginn
-19,51 %
1 Jahr
-77,97 %
3 Jahre
Wikifolio
Passender Service zu Compass Pathways PLC (Spons.ADRs) o.N.
Webinar zu Compass Pathways PLC (Spons.ADRs) o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)5,010-12,750
- Jahrestief / Hoch ($)5,730-12,750
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Compass Pathways PLC (Spons.ADRs) o.N.
Keine Dividenden verfügbar
Termine von Compass Pathways PLC (Spons.ADRs) o.N.
Keine aktuellen Termine
Beschreibung
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
